BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:44 PM
 | 
Dec 13, 2011
 |  BC Extra  |  Clinical News

Celgene reports pomalidomide data in MM

Celgene Corp. (NASDAQ:CELG) said oral pomalidomide plus low-dose dexamethasone led to a median progression-free survival (PFS), the primary endpoint, of 4.7 months vs. 2.7 months for...

Read the full 119 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >